China Pharma Holdings, Inc. (CPHI) stock

CPHINYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30

$0.54−0.01 (-1.43%)

Close on Nov 11, 2026Market cap $23.37MP/E –Yield –

China Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

China Pharma's EV/EBITDA was 559.7× on Apr 29, 2022, against 8.4× a year earlier. Over the last 3 years it ranged from 6.1× to 890.8×, with a median of 16.0×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2022	Apr 29, 2022	559.7×	+415.1
2016	Jul 29, 2016	144.6×	+12.6
2013	Jul 31, 2013	132.0×	+125.9
2012	Dec 31, 2012	6.1×	−4.9
2011	Dec 30, 2011	11.0×	–

Where these numbers come from

Parsed from the XBRL in China Pharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Apr 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CPHI.

Compare: CPHI vs SXTC · CPHI vs PMHS · CPHI vs PTCHF · CPHI vs ANL · CPHI vs KYNB

Revenue growth-11.0% · median 3825.8%

Gross margin11.8% · median 33.7%

Operating margin-111.8% · median -692.4%

Net margin-114.3% · median 1834.7%

Company	Revenue	Growth
KYNB	$4.62M	-37.1%
CPHI	$3.91M	-11.0%
PMHS	$3.17M	+7688.8%
SXTC	–	–
PTCHF	–	–
ANL	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 221
Held by institutions: 0.5%
Auditor: Enrome LLP
SEC CIK: 1106644

Advertisement
300 × 250

See a number that looks wrong?

China Pharma EV/EBITDA

EV/EBITDA at the end of each year

More China Pharma figures